Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage

• DOI: 10.1002/hep.27006
• Publication Date: 2014-01-10T19:16:45Z
• Authors: Yeon Seok Seo; Soo Young Park; Moon Young Kim; Ju Hyun Kim; Jun Yong Park; Hyung Joon Yim; Byoung Kuk Jang; Hong Soo Kim; Taeho Hahn; Byung Ik Kim; Jeong Heo; Hyonggin An; Won Young Tak; Soon Koo Baik; Kwang Hyub Han; Jae Seok Hwang; Sang Hoon Park; Mong Cho; Soon Ho Um
• Keywords: Terlipressin

Vasoactive drugs are recommended to be started as soon possible in suspected variceal bleeding, even before diagnostic endoscopy. However, it is still unclear whether the therapeutic efficacies of various vasoactive used comparable. The aim this prospective, multicenter, randomized, noninferiority trial was characterize effects terlipressin, somatostatin, and octreotide when they initiated endoscopic treatment patients with acute bleeding. Patients liver cirrhosis significant upper gastrointestinal bleeding were randomly assigned receive early administration or octreotide, followed by treatment. nonvariceal excluded after primary endpoint 5-day success, defined control without rescue treatment, rebleeding, mortality, a margin 0.1. In total, 780 enrolled: 261 terlipressin group; 259 somatostatin 260 group. At time initial endoscopy, active noted 43.7%, 44.4%, 43.5% these patients, respectively ( P = 0.748), success achieved day 5 86.2%, 83.4%, 83.8% 0.636), similar rates (89.7%, 87.6%, 88.1%; 0.752), rebleeding (3.4%, 4.8%, 4.4%; 0.739), mortality (8.0%, 8.9%, 8.8%; 0.929). absolute values lower bound confidence intervals for versus terlilpressin 0.095, 0.090, 0.065, respectively. Conclusion : Hemostatic safety did not differ significantly between adjuvants gastroesophageal (Hepatology 2014;60:954–963)